Should we continue to use tenofovir disoproxil fumarate/lamivudine/dolutegravir for treatment of pregnant women? Interpreting the PROMISE trial.

IF 3.4 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2024-07-15 Epub Date: 2024-06-27 DOI:10.1097/QAD.0000000000003911

Andrew M Hill, Daniel Elbirt

引用次数: 0

查看原文本刊更多论文

我们是否应该继续使用替诺福韦酯/拉米夫定/多拉韦酯治疗孕妇？解读PROMISE试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.